Post-earnings recap
Reported
Mon, Aug 5, 2024
EPS actual
$-0.31
EPS est.
$-0.34
EPS surprise
+10.14%
1-day move
-2.01%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Terns Pharmaceutical reported a wider-than-expected loss per share, which was better than some analysts anticipated. However, the lack of revenue details and no guidance update may have contributed to the stock's decline of 2.01%. Investors may be concerned about the company's future growth prospects without clearer financial direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.31 | N/A | +10.14% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a sense of cautious optimism about future developments. They emphasized their commitment to advancing their product pipeline.
Management expressed confidence in their ongoing projects and pipeline.
They highlighted the importance of upcoming trials and their potential impact.